BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21911935)

  • 21. Tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a ras-independent pathway.
    Kashiwada M; Shirakata Y; Inoue JI; Nakano H; Okazaki K; Okumura K; Yamamoto T; Nagaoka H; Takemori T
    J Exp Med; 1998 Jan; 187(2):237-44. PubMed ID: 9432981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes.
    Bergh JC
    Am Rev Respir Dis; 1990 Dec; 142(6 Pt 2):S20-6. PubMed ID: 2174659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Src Promotes Metastasis of Human Non-Small Cell Lung Cancer Cells through Fn14-Mediated NF-κB Signaling.
    Wang W; Liu F; Wang C; Wang C; Tang Y; Jiang Z
    Med Sci Monit; 2018 Mar; 24():1282-1294. PubMed ID: 29500337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRAF6 promotes the progression and growth of colorectal cancer through nuclear shuttle regulation NF-kB/c-jun signaling pathway.
    Zhu G; Cheng Z; Huang Y; Zheng W; Yang S; Lin C; Ye J
    Life Sci; 2019 Oct; 235():116831. PubMed ID: 31487530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Competition between TRAF2 and TRAF6 regulates NF-kappaB activation in human B lymphocytes.
    Zhang W; Zhang X; Wu XL; He LS; Zeng XF; Crammer AC; Lipsky PE
    Chin Med Sci J; 2010 Mar; 25(1):1-12. PubMed ID: 20449947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the activation of the myc family oncogene and of its stability over time in xenografted human lung carcinomas.
    Gazzeri S; Brambilla E; Chauvin C; Jacrot M; Benabid AL; Brambilla C
    Cancer Res; 1990 Mar; 50(5):1566-70. PubMed ID: 2154327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
    Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
    Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
    Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
    Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.
    Xie C; Zhang LZ; Chen ZL; Zhong WJ; Fang JH; Zhu Y; Xiao MH; Guo ZW; Zhao N; He X; Zhuang SM
    Hepatology; 2020 May; 71(5):1660-1677. PubMed ID: 31509261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cleavage and polyadenylation specific factor 4 targets NF-κB/cyclooxygenase-2 signaling to promote lung cancer growth and progression.
    Yi C; Wang Y; Zhang C; Xuan Y; Zhao S; Liu T; Li W; Liao Y; Feng X; Hao J; Gao Y; Yu W; Chen Y; Zhang C; Guo W; Tang B; Deng W
    Cancer Lett; 2016 Oct; 381(1):1-13. PubMed ID: 27450326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PDLIM2 acts as a cancer suppressor gene in non-small cell lung cancer via the down regulation of NF-κB signaling.
    Shi H; Ji Y; Li W; Zhong Y; Ming Z
    Mol Cell Probes; 2020 Oct; 53():101628. PubMed ID: 32621848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers.
    Suzuki M; Shigematsu H; Shames DS; Sunaga N; Takahashi T; Shivapurkar N; Iizasa T; Minna JD; Fujisawa T; Gazdar AF
    Ann Surg Oncol; 2007 Apr; 14(4):1397-404. PubMed ID: 17195088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TRAF6 Promoted Tumor Glycolysis in Non-Small-Cell Lung Cancer by Activating the Akt-HIF
    Feng L; Feng S; Nie Z; Deng Y; Xuan Y; Chen X; Lu Y; Liang L; Chen Y
    Biomed Res Int; 2021; 2021():3431245. PubMed ID: 34409101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
    Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of genetic and molecular events in the pathogenesis of lung cancer.
    Johnson BE; Kelley MJ
    Chest; 1993 Jan; 103(1 Suppl):1S-3S. PubMed ID: 8380130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRAF6 is functional in inhibition of TLR4-mediated NF-κB activation by resveratrol.
    Jakus PB; Kalman N; Antus C; Radnai B; Tucsek Z; Gallyas F; Sumegi B; Veres B
    J Nutr Biochem; 2013 May; 24(5):819-23. PubMed ID: 22925919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tripartite motif-containing 37 (TRIM37) promotes the aggressiveness of non-small-cell lung cancer cells by activating the NF-κB pathway.
    Li Y; Deng L; Zhao X; Li B; Ren D; Yu L; Pan H; Gong Q; Song L; Zhou X; Dai T
    J Pathol; 2018 Nov; 246(3):366-378. PubMed ID: 30043491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
    Zhang J; Lei Z; Huang Z; Zhang X; Zhou Y; Luo Z; Zeng W; Su J; Peng C; Chen X
    Oncotarget; 2016 Nov; 7(48):79557-79571. PubMed ID: 27791197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.
    Lu Y; Hippen KL; Lemire AL; Gu J; Wang W; Ni X; Ranganathan P; Levine BL; Riley JL; June CH; Turka LA; Munn DH; Garzon R; Lu L; Blazar BR
    Blood; 2016 Sep; 128(10):1424-35. PubMed ID: 27485827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.